DHR Health: Pioneering Alzheimer’s Treatment Breakthrough South of San Antonio

Translate to Spanish or other 102 languages!

Dr. R. Alejandro Cruz, DHR Health Neurologist. Photo Courtesy DHR Health
- Advertisement -

Edinburg, Texas: DHR Health, a leader in healthcare innovation, proudly announced today its groundbreaking achievement as the first hospital south of San Antonio to successfully administer Leqembi, an FDA-approved medication for the early treatment of Alzheimer’s disease. This milestone demonstrates their expertise and is a significant advancement in healthcare for the Rio Grande Valley.

Under the expert guidance of neurologist Dr. R. Alejandro Cruz and the dedicated team at the DHR Health Neuroscience Institute, comprehensive protocols have been meticulously developed for administering Leqembi. These protocols encompass every aspect of patient care, from initial assessments to laboratory testing, radiology procedures, and establishing a state-of-the-art infusion center.

“I am very proud of the hard work of our team at DHR Health. Being the first facility to provide this groundbreaking therapy for Alzheimer’s disease marks a new era of hope for our community,” said Dr. R. Alejandro Cruz, DHR Health Neurologist.

- Advertisement -

As the largest physician-owned hospital in the United States and a leading healthcare provider in the Rio Grande Valley, DHR Health is immensely proud to be at the forefront of Alzheimer’s disease treatment in South Texas. “This achievement represents our ongoing commitment to bringing innovative and advanced treatment options to our community. We are proud to provide world-class care close to home,” said Marissa Castañeda, Senior Executive Vice President at DHR Health.

Dr. Cruz explains that Alzheimer’s disease is a progressive brain disorder characterized by changes in the brain that lead to the accumulation of certain proteins. These changes cause the brain to shrink and brain cells to die, resulting in dementia, which manifests as a gradual decline in memory, thinking, behavior, and social skills. The introduction of Leqembi offers hope for those affected by this debilitating condition, with the potential to improve quality of life and slow disease progression.

DHR Health continues delivering exceptional care, announcing a new chapter in Alzheimer’s treatment for the Rio Grande Valley. If you or a loved one are affected by Alzheimer’s, we encourage you to take the next step. To learn more about this groundbreaking treatment or to make an appointment, please contact the DHR Health Neuroscience Institute at (956) 362-8500.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves First Factor Xla Inhibitor to Help Prevent Stroke in Certain Adults at High Risk 

The U.S. Food and Drug Administration today approved Sunharbo (asundexian) 50 mg tablets, the first factor XIa (FXIa) inhibitor for use in combination with antiplatelet therapy to reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke (a stroke caused by a clot that did not originate in the heart) or a high-risk transient ischemic attack (TIA), often called a “mini-stroke.” 

DHR Health Expands Ophthalmology Services with Addition of Dr. Rachel Gelman

 Continuing its mission to provide exceptional medical care to patients across the Rio Grande Valley, DHR Health is pleased to welcome ophthalmologist Dr. Rachel Gelman to its team of healthcare providers.

STHS McAllen Welcomes Aspiring Youth for an Interactive Look Inside Healthcare

As the demand for healthcare professionals continues to grow, introducing young students to the wide range of opportunities available in the medical field is more important than ever. From nurses and physicians to emergency responders, pharmacists and other essential healthcare workers, each plays a critical role in caring for patients and keeping communities healthy.

South Texas Health System Invests $25,000 in VIDA to Expand Healthcare Career Opportunities in the RGV

To help address the ongoing need for qualified workers in the Rio Grande Valley, South Texas Health System (STHS) has renewed its support of Valley Initiative for Development and Advancement (VIDA) through a $25,000 annual grant.
- Advertisement -